GIP and obesity due to melanocortin 4 receptor deficiency: The potential mechanisms through which GLP-1 and GIP/GLP-1 receptor agonists recalibrate and normalize the fat mass and body weight setpoint in patients with obesity may stem from their primary effects on incretin homeostasis.